Covid Trial

SI says 45% interim readout in early November, which would indicate to me its going to be hard to have this trial finished by the end of the year based on current numbers?, though new hospitals have come on board in recent weeks. If DSMB says continue on with the trial based on November readout , would this be an indication that the treatment is working but based on Baysian stats not enough at this stage to stop trial due to its effectiveness?. How good or neutral is the possible news from DSMB saying continueon with the trial after Novembers readout. I understand taking the trial to completion could be very good for MSB as it gives complete results and hence data for ARDS etc and the FDA?.
Also i know Grossman has said mortality rate for SOC is 60% but if its say 50% and MSB has 75% success rate (is this to ambitious) and reduced hospital stay with possible lung damage repair?. How good would these results be? i would assume they would be significant for patients and for MSB.
I have read some excellent posts on this subject just trying to think what the market would think if in November DSMB says continue on with the trial to at least next interim readout?